Tolero Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013490)
◆英語タイトル:Tolero Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013490
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:34
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Tolero Pharmaceuticals Inc (Tolero), a subsidiary of Dainippon Sumitomo Pharma America Holdings Inc, is a drug company that offers medicines to treat cancer and other serious human diseases. The company’s alvocidib is a cyclin dependent kinase inhibitor with selective activity against CDK9 and also CDK4/6. Tolero’s alvocidib is also indicated for various types of cancer including solid tumors and hematological malignancies. The company’s preclinical stage products include TP-1287, TP-0903 and TP-0184. Its inhibitors provide treatment for diseases that accumulate abnormalities in cell functions such as mutation, amplification, deletion, and others. Tolero is headquartered in Lehi, Utah, the US.

Tolero Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Tolero Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 11
Venture Financing 13
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 13
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 14
Tolero Pharma Raises US$3.33 Million In Venture Financing 15
Partnerships 16
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 16
Licensing Agreements 17
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 17
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 18
Acquisition 19
Sumitomo Dainippon Pharma Acquires Tolero Pharma 19
Tolero Pharmaceuticals Inc – Key Competitors 21
Tolero Pharmaceuticals Inc – Key Employees 22
Tolero Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Product News 24
11/15/2016: Tolero Pharmaceuticals to Present Progress of Leukemia Program at the 58th ASH Annual Meeting and Exposition 24
06/13/2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 25
06/06/2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress 26
06/06/2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress 27
04/20/2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Multiple Drug Combination Strategies Due to the Targeting of MCL-1 28
Clinical Trials 29
Nov 15, 2016: Tolero Pharmaceuticals to Present Progress of Anemia Program at the 58th ASH Annual Meeting and Exposition 29
Apr 18, 2016: Tolero Pharmaceuticals Presents Data Demonstrating AXL Inhibition Leads to a Reversal of a Mesenchymal Phenotype Sensitizing Cancer Cells to Targeted Agents and Immuno-Oncology Therapies 30
Apr 12, 2016: Tolero Pharmaceuticals to Present Update on Alvocidib at the AACR Annual Meeting 2016 31
Apr 12, 2016: Tolero Pharmaceuticals to Present Update on TP-0903 at the AACR Annual Meeting 2016 32
Mar 08, 2016: Tolero Pharmaceuticals to Present at the 13th Annual BIO Asia International Conference 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tolero Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Tolero Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tolero Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 11
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 13
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 14
Tolero Pharma Raises US$3.33 Million In Venture Financing 15
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 16
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 17
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 18
Sumitomo Dainippon Pharma Acquires Tolero Pharma 19
Tolero Pharmaceuticals Inc, Key Competitors 21
Tolero Pharmaceuticals Inc, Key Employees 22

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Tolero Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析(Tolero Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆